retatrutide phase 2 trial new england journal of medicine (“reta”) is an experimental weight-loss drug currently in 3 clinical trials. It's a once-weekly injection similar to Ozempic and Mounjaro—but more powerful. The reason comes down to how it works The Science Behind Retatrutide: A

The absorption of glutathione and other substances from the gastrointestinal tract 38 and oral mucosa 39 has been the subject of some studies and it is now well known that orally administered glutathione cannot be relied upon for therapeutic purposes

10.1016/j.chmed.2019.11.002 57 ParkJ

Side effect comparison: Nausea: Tirzepatide rates range from 12% to 33% depending on dose, comparable to cagrilintide Vomiting: Tirzepatide higher than cagrilintide Diarrhea: Similar rates Injection site reactions: Cagrilintide significantly higher than tirzepatide Fatigue: Tirzepatide fatigue is commonly reported, comparable to cagrilintide Some researchers are exploring cagrilintide combined with tirzepatide for potentially enhanced effects

However, stronger muscles support joints reducing injury risk and improving rehabilitation outcomes

We see dramatic reductions in weight in patients taking these drugs